Monoclonal antibodies specific for aflatoxin In a competitive radioimmunoassay using [3H]aflatoxin B1, 3
covalently bound to bovine gamma globulin. The aflatoxinmodified protein used to immunize mice was produced chemically by activating aflatoxin B1 to a 2,3-epoxide derivative, which then covalently bound to the protein. One of the monoclonal antibodies isolated (2B11) was found to be a high-affinity IgM antibody with an affinity constant for aflatoxin B1, aflatoxin B2, and aflatoxin M1 of about 1 x 109 liters per mol.
In a competitive radioimmunoassay using [3H]aflatoxin B1, 3 pmol (1 ng) of aflatoxin B1, aflatoxin B2, or aflatoxin M1 caused 50% inhibition with this antibody. The antibody also had significant cross-reactivity for the major aflatoxin-DNA adducts: 2,3-dihydro-2-(N7-guanyl)-3-hydroxyaflatoxin B1 and 2,3-dihydro-2-(N5-formyl-2',5',6'-triamino-4'oxo-N5-pyrimidyl)-3-hydroxyaflatoxin Bl. The antibody was also covalently bound to Sepharose-4B and used in a column-based solid-phase immunosorbent assay system. Aflatoxins added in vitro to phosphate buffer, human urine, human serum, or human milk at levels expected to be obtained in human samples acquired from environmentally exposed individuals were quantitatively recovered by applying the mixture to this antibody affinity column purification system. Preliminary studies using urine samples from rats injected with radiolabeled aflatoxin B1 have also indicated that aflatoxin metabolites can be isolated by these methods. Furthermore, we have found that the monoclonal antibody affinity columns can be regenerated for multiple use. Therefore, the monoclonal antibodies and their application to affinity chromatography represents a useful and rapid technique to purify environmentally occurring levels of this carcinogen and some of its metabolites for quantitative measurements.
The aflatoxins are highly toxic and carcinogenic compounds, which are consistently found contaminating human food supplies in many areas of the world, and are epidemiologically linked to increased incidences of human liver cancer in Asia and Africa (1) (2) (3) . Adverse biological consequences resulting from exposure to aflatoxin B1 (AFB1) are thought to be related to its ability to be oxidatively metabolized by constituative cellular enzymes. Of particular importance may be the ability of AFB1 to form covalently linked adducts with cellular macromolecules, including DNA. It is well established that AFB1 forms covalent DNA adducts following enzymatic oxidation to a highly reactive 2,3-epoxide, which nucleophil. ically attacks the N7 atom of guanine (4-6). The major DNA lesion produced by this reaction, 2,3-dihydro-2-(N7-guanyl)-3-hydroxyaflatoxin B1 (AF-N7-Gua), has been studied as an indicator compound of genotoxic damage to the cellular genetic material (7) (8) (9) .
A major objective of our work has been the development of noninvasive screening procedures for assessing the exposure of humans to environmentally occurring carcinogens. Useful protocols require an ability to quantify chemical carcinogens and their metabolites, especially DNA adducts, in readily accessible body fluids, such as serum and urine. We have been developing these screening methodologies by using immunoassays with monoclonal antibodies. We previously have reported production of monoclonal antibodies that recognize aflatoxin-DNA derivatives (10, 11) . These early antibodies were found to be specific for AFBl-adducted DNA and in a competitive ELISA were able to detect AFB1 residues in DNA down to a level of 1 per 1,355,000 nucleotides (11) . However, these antibodies did not recognize AFB1, free aflatoxin-DNA adducts, or any other metabolites. Another laboratory has also reported the production of a monoclonal antibody that recognizes DNA containing 2, 3-dihydro-2-(N5-formyl-2' ,5' ,6'-triamino-4'-oxo-N5-pyrimidyl)-3-hydroxyaflatoxin B1 (AF-FAPyr) in DNA (12).
We were encouraged by these preliminary results to continue attempts to produce monoclonal antibodies with properties necessary to detect aflatoxins and their derivatives in environmental samples.
We report here the production of a high affinity IgM monoclonal antibody that recognizes aflatoxin Bl, aflatoxin B2, aflatoxin M1, and the major aflatoxin-DNA adducts; AF-N7-Gua and AF-FAPyr. This antibody was used to construct a reusable antibody affinity chromatographic column capable of isolating aflatoxins from complex biological fluids, such as serum, urine, and milk. Initial applications of this antibody affinity column in development of analytical methods are also discussed.
MATERIALS AND METHODS
Cell Fusion. The myeloma cell line used for fusion, SP-2, was maintained in suspension in Dulbecco's modified Eagle's medium supplemented with 20% (vol/vol) fetal calf serum, glutamine, penicillin, streptomycin and nonessential amino acids (GIBCO). The cell fusion procedures have been described (13) .
Preparation of AFB,-Bovine Gamma Globulin (AFB1-BGG)
Immunogen. BGG (Calbiochem) was dissolved in phosphatebuffered saline (P1/NaCl) (pH 7.0) at 10 mg/ml. The BGG Abbreviations: AFB1, aflatoxin B1; AFB2, aflatoxin B2; AFQ1, aflatoxin Ql; AFM1, aflatoxin M1; AFG1, aflatoxin G1; AFG2, aflatoxin G2; AF-N7-Gua, 2,3-dihydro-2-(N7-guanyl)-3-hydroxyaflatoxin B19 AF-FAPyr, 2,3-dihydro-2-(N5-formyl-2',5',6'-triamino-4'-oxo-Npyrimidyl)-3-hydroxyaflatoxin B1; Me2SO, dimethyl sulfoxide; BGG, bovine gamma globulin; BSA, bovine serum albumin. tTo whom reprint requests should be addressed.
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Proc. NatL Acad. Sci USA 81 (1984) 7729 was derivatized with AFB1 by using a modified chemical procedure with m-chloroperoxybenzoic acid as described by Martin and Garner (6) . In a typical reaction, 1 mg of AFBI (3.2 ,umol) was dissolved in 2 ml of methylene chloride and added to a 5-molar excess of m-chloroperoxybenzoic, also dissolved in 2 ml of methylene chloride. BGG in buffer was added to the reaction mixture to produce a 5-molar excess of AFB1 relative to the protein content. The mixture was vigorously stirred overnight at ambient temperature. The reaction was terminated by centrifuging at 2,000 x g for 20 min. The aqueous epiphase containing the modified protein was then extensively dialyzed against P1/NaCl (pH 7.4). The level of modification of the protein was quantified by absorbance at 362 nm using a molar extinction coefficient of 18,000. In a typical reaction, there were 40-50 AFB1 residues bound per molecule of BGG. Enzyme Immunoassays. ELISA was used to determine aflatoxin-specific antibodies in mouse sera and hybridoma media. Procedures used were modifications of previously described protocols (10, 11) . Briefly, polyvinyl chloride microtiter plates (Dynatech, Alexandria, VA) containing in each well 50 /ul of AFB1-BSA dissolved in P1/NaCl at 2 ,tg/ml were incubated for 2-4 hr at ambient temperature.
Control plates containing 50 ,Al of BSA in P1/NaCl at 2 ,g/ml were treated similarly. Antigen solution was aspirated, and the plates were washed three times with tap water. Solutions containing 0.2% BSA or 0.2% gelatin, type IV (Sigma), both in Pi/NaCl were added, and the plates were incubated for 1 hr at ambient temperature, a procedure designed to limit nonspecific binding of antibodies. The plates were washed in tap water, and 50 ,l of mouse sera or hybridoma media was added to each well. To titer the mouse sera, 1:3 serial dilutions in 10% horse serum were prepared over a range from 1:50 to 3:50,000. In the case of hybridoma media, 50-,Al aliquots were used without dilution. Plates were incubated for 90 min at 37°C, after which they were thoroughly washed. Specific antibodies bound to the plate were detected by incubating 50 ,l per well of a 1:200 dilution of rat anti-mouse K chain antibody coupled with alkaline phosphatase for 2 hr at ambient temperature. The plates were rewashed and incubated with 100 ,ul per well of p-nitrophenyl phosphate (Sigma) at 1 mg/ml in 0.1 M diethanolamine buffer (pH 9.8).
Quantitation of the p-nitrophenol production was performed by measuring absorbance at 405 nm with a microtiter plate reader (Dynatech, Alexandria, VA).
The isotypes of the monoclonal antibodies were determined in noncompetitive ELISA by using the mouse immunoglobulin subtype identification kit purchased from Boehringer Mannheim.
Competitive Radioimmunoassay. sample, consisting of nonradiolabeled AFB1 or its metabolites, were added to the tube in a 100-pil volume. The reaction mixture was then incubated at ambient temperature for 2 hr, following which the mixture was brought to a volume of 1-ml with P1/NaCl. An equal volume of ice-cold saturated ammonium sulfate was then added; the sample was mixed and allowed to stand on ice for 15 min. The sample was then centrifuged for 15 min at 2,000 x g, and the percentage of inhibition in the reaction was determined by the method of Muller (14) . Isolation and Purification of Monoclonal Antibodies. Hybridomas secreting antibodies of interest were grown as ascites tumor cells in BALB/c mice, which previously had been injected with 0.5 ml of pristane (Aldrich). Ascites fluid collected from these animals were pooled and either used directly in the immunoassays or further purified by saturated ammonium sulfate precipitation and dialysis against Pi/ NaCl.
The IgM monoclonal antibody (2B11) was further purified by HPLC with a TSK 4000SW column and isocratic elution at 0.5 ml per min. Proteins were monitored at 280 nm, and IgM and IgG standards purchased from Cappel Laboratories (Cochranville, PA) were used as molecular weight standards. Using this procedure, we were able to isolate up to 1 mg of chromatographically pure 2B11 per HPLC run.
Preparation of Monoclonal Antibody Affinity Column. A monoclonal antibody affinity column was prepared by the procedures described by Pharmacia. The monoclonal antibody (2B11) was dissolved in coupling buffer (0.1 M NaHCO3, pH 8.3/0.5 M NaCl) at 1 mg/ml. This solution was coupled to 2.5 g of cyanogen bromide-activated Sepharose-4B (SIGMA). The resin had been incubated in 8 ml of 1 mM HCl overnight. The unbound sites of the antibody-bound gel were blocked by incubating the gel with 1.0 M ethanolamine (pH 8.5). For the data reported in this paper, a 2-ml bed volume of the affinity gel was used. The flow rate for the separations was about 0.5 ml/min. All procedures were performed at ambient temperature.
HPLC. All HPLC were performed with a Beckman model 324MP gradient liquid chromatograph equipped with a Beckman model 160 UV detector. For steric-exclusion chromatography of TSK 4000SW column (Beckman) was used at 0.5 ml per min in P1/NaCl. For Muller (14) , respectii were derived from data obtained by the co scribed above. The specificity of 2B11 i RIA for AFB1 and its metabolites, inc AFB1-DNA adducts (AF-N7-Gua and Al picted in Figs. 1 and 2 . The 50% inhibition AFB2, and AFM, were found to be 3.0 prr those for AFG1, AFG2, and AFQ1 were 60 pmol, respectively. These data clearly inc jor epitope for 2B11 recognition of aflato: marin ring and the cyclopentenone ring of ecule. Fig. 2 depicts the specificity and 50% competitive RIA of 2B11 for AFB1 and tl toxin-DNA adducts, AF-FAPyr and AFinhibition values were 3.0, 24.0, and 89.0 p Based on the data in Fig. 1 , we expected E the antibody for the two aflatoxin-DNA tion, data in Fig. 2 indicate that the antiboi more sensitive in detecting (24.0 pmol ver AF-FAPyr adduct than the AF-N7-Gua as was unanticipated, since the aflatoxin mc these adducts when compared to the parei observations suggest that the epitope for be partially obstructed in these DNA as stereochemistry of covalent binding of af Experiments (data not shown) using AF and BSA in the competitive RIA determ inhibition for these macromolecularly bou 10.0 and 12.0 pmol in a 300-/LA assay, rn data tend to support the suggestions that nized by the monoclonal antibody may hindered when AFB1 is coupled to a larg Solid-Phase Affinity Chromatography v nal Antibody 2B11. Ascites fluid contain was initially fractionated by precipitation monium sulfate, followed by dialysis aga antibody was then further purified by HI clusion (molecular weight separation) mode, which was used to take advantage lar weight of the IgM (900,000) in purific clonal antibody. The purified antibody, hi for activity by noncompetitive RIA, was phase matrix of Sepharose-4B. The capacity of the antibody affinity column to bind AFB1 aving been assayed was determined by radiometric and absorbance techniques , bound to a solidand was found to be able to bind 1-1.3 ,ug of AFB1 from 10 nns made for these ml of P,/NaCl per 1 ml of column bed volume. [14C]AFB, per kg of body weight and their urine was collected for 20 hr, at which time 10-12% of the 14C of the initial dose had been excreted into the urine. Aliquots (100 jul) of each urine containing 290 and 310 ng of aflatoxin, respectively, were diluted with 1.9 ml of P1/NaCl and applied to the antibody affinity column, and 65% of the applied 4C became bound to the antibody matrix. This material was eluted from the column with 50% Me2SO buffer and analyzed by reversed-phase HPLC. Preliminary analysis of this fraction revealed that AFM1 was the major metabolite isolated by the antibody affinity column.
These findings indicate that the protocol outlined in the following flow chart will be a useful preparative technique to isolate and purify aflatoxin B1 and its metabolites from complex biological samples obtained from environmentally exposed populations. The samples obtained can then be quantitatively analyzed by methods such as HPLC and immunoassay techniques. (15) , based upon the isolation of aflatoxin DNA adducts from human urine by preparative and analytical liquid chromatography. Radiometric labeling techniques were used to achieve a limit of detectability in spiked samples of 1 pg of AF-N7-Gua per ml of urine. However, we found that when attempting to apply these methods to in vivo urine samples, nonspecific interfering materials present in urine sample often prevented the attainment of this level of sensitivity. Therefore, we have undertaken efforts to combine chemical analytic procedures with a monoclonal antibody affinity chromatography column.
The development of a reusable monoclonal antibody affinity chromatographic column first required the production of high-affinity monoclonal antibodies recognizing aflatoxins. Our initial endeavors to produce monoclonal antibodies that recognize aflatoxins culminated in the production of five antibodies, which were found to be specific for AFB1-adducted DNA and, in a competitive ELISA, showed a limit of detectability of one AFB1 residue per 1,355,000 nucleotides (10, 11) . Since these antibodies did not cross-react with the aflatoxin derivatives expected to be found in human urine and serum samples, we continued attempts to produce highaffinity monoclonal antibodies with the desired properties. One of these, an IgM (2B11) that was found to have a particularly high affinity towards the aflatoxins (16), was used in the studies described in this report. In the competitive RIA, a 50% inhibition value of about 3 pmol is routinely obtained with this antibody, and there is a lower limit of detectability of about 300 fmol for AFB1, AFB2 and AFM1. Furthermore, we expect that by using more sensitive competitive ELI-SA/USERIA (ultrasensitive enzyme-linked RIA) techniques, the ultimate sensitivity with this antibody in detecting aflatoxins will be further enhanced (10, 11) . We also have found that when this antibody is bound to a solid-phase matrix, a reusable column can be prepared that selectively isolates aflatoxins from complex mixtures, such as urine, serum, and milk. Isolates from this column chromatographed by HPLC show very little contamination by nonaflatoxin derivatives. We are now in the process of validating this technique by using urine samples isolated from rats injected with radiolabeled aflatoxin B1.
